Chris Ntoumenopoulos
Non-executive Chairperson

Mr. Ntoumenopoulos is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm. Chris has extensive experience in financial markets, with over 20 years of raising capital and providing corporate advisory services. Additionally, he has served as a director of ASX listed companies for more than 7 years.

Dr Tony Keating
Executive Director (Part time)

Dr Keating is an experienced entrepreneur and CEO, having co-founded and led ResApp Health from start-up to its ultimate acquisition by Pfizer for $180 million. Following the sale of ResApp, Tony took on the role of Vice President at Pfizer leading the integration of ResApp’s business in Pfizer. Not only is Dr Keating extremely respected in the industry, but his international network is also second to none.

Dr Anton Uvarov, PhD, MBA
Non-Executive Director

Founding director of Actinogen Medical (ASX:ACW) an advanced Alzheimer’s biotechnology company. Non-executive director at Nutritional Growth Solutions (ASX:NGS). Former Equities Analyst with Citigroup, US and former director at Dimerix (ASX:DXB) and Imugene (ASX:IMU).

Clarke Barlow
Non-executive Director

Mr. Barlow is a Financial Adviser and Capital Markets Specialist with over 20 years’ experience in the Financial Services Industry in Australia and the United Kingdom. Clarke has extensive experience providing corporate advisory services for companies listed on the ASX across a variety of industries, with a particular focus on growth opportunities in the Biotechnology, Technology, Industrial and Resources industries.

Chris Achurch
Company Secretary

Mr. Achurch has considerable experience in the exploration, mining, agricultural, biotechnology, accounting and finance sectors having worked both in Australia and the United States. Chris is a member of the Institute of Chartered Accountants Australia and New Zealand and provides company secretarial, corporate advisory and general consulting services to a number of ASX-listed Companies.

Clinical Professor Allan Kermode, MBBS, MD, FRACP, FRCP
Scientific Advisor

Clinical Professor Allan Kermode is a Consultant Neurologist and Head of the Demyelinating Diseases Research at the Perron Institute, Clinical Professor of Neurology at the University of Western Australia and Visiting Professor at Sun Yat Sen University, PR China. Former Head of the Department of Neurology and Clinical Neurophysiology at Sir Charles Gairdner Hospital. Previous appointments include Oxford University Dept of Neurology, Institute of Molecular Medicine, National Hospital for Neurology in London, UK, and National Institutes of Health, USA. Professor Kermode sees patients with multiple sclerosis (MS), manages a research team investigating causes of MS, and is Professor of Immunology at the Institute for Immunology and Infectious Diseases (IIID) based at Murdoch University, where he also conducts MS clinics.

Professor Dao-Yi Yu
Scientific Advisor

Head of Physiology & Pharmacology, Lions Eye Inst Clinical ophthalmologist with >25 years in ocular research. Lead inventor of numerous patents including a system for ocular ultrasurgery, ocular tonometer and biological microfistula. Appointments include Professor, Centre for Ophthalmology & Visual Science at UWA and Adjunct Professor, Dept. Ophthalmolgy & Visual Sciences at Dalhousie University of Medicine.

Dr Frank Bonner, PhD, BSc
Scientific Advisor

Dr Bonner has >35 years of experience in toxicology and non-clinical drug development, working for pharmaceutical (Senior Vice President, Sanofi), and contract research industries, in addition to 15 years as an independent consultant. He brings comprehensive knowledge across all aspects of regulatory guidance and advocacy and outsourced programme management. Dr Bonner has served as a Scientific Advisor for a number of technology and drug development SME’s and has Board level experience including Executive Director, Stem Cells for Safer Medicines; Non-Executive Chairman, Maccine Pte, Singapore; Executive Director, Life Science Research Inc. etc. He is a fellow of the British Toxicology Society, Past President of the Society and Visiting Professor in the Division of Integrative Systems Medicines at Imperial College, London.

Dr. Peter Hnik, MD, MHSc
Scientific Advisor

Dr Peter Hnik is an ophthalmologist with special interests including glaucoma and neuro-ophthalmology. He received his Medical Degree from Charles University in Prague and a Master of Health Science from the University of British Columbia, Canada. He served as Director and Chief Medical Officer at iCo Therapeutics Inc. and Associate Director of Clinical Research at QLT Inc. Dr Hnik is currently President of Clinscape Consulting Inc. where he specialises in designing preclinical packages and clinical programs across a range of ophthalmic and other indications. Dr Hnik is a member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA), and the Drug Information Association (DIA).